Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$2.41
-0.4%
$2.04
$1.11
$5.00
$641.40M1.811.57 million shs1.50 million shs
Journey Medical Corporation stock logo
DERM
Journey Medical
$7.19
-1.5%
$7.05
$3.54
$8.25
$167.50M0.891,814 shs64,122 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.95
+1.0%
$1.86
$1.33
$2.89
$57.66M1.75415,007 shs213,214 shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$13.22
+7.0%
$10.97
$5.35
$16.15
$721.77M1.14680,253 shs1.55 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
0.00%-2.43%+16.99%+68.53%-45.60%
Journey Medical Corporation stock logo
DERM
Journey Medical
0.00%+0.56%+13.23%+15.04%+25.48%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
0.00%+3.17%+7.73%+27.45%-3.47%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
0.00%+11.47%+14.26%+71.91%-3.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
2.7062 of 5 stars
3.51.00.00.02.53.30.6
Journey Medical Corporation stock logo
DERM
Journey Medical
2.277 of 5 stars
3.51.00.00.02.81.70.6
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.5855 of 5 stars
3.51.00.00.02.13.30.6
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
4.2426 of 5 stars
3.61.00.04.83.10.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
3.00
Buy$9.32286.72% Upside
Journey Medical Corporation stock logo
DERM
Journey Medical
3.00
Buy$9.5032.13% Upside
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.00976.92% Upside
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3.29
Buy$25.8095.16% Upside

Current Analyst Ratings Breakdown

Latest DERM, FBIO, AUTL, and STOK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
7/1/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
6/12/2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/15/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $35.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$10.12M63.38N/AN/A$1.61 per share1.50
Journey Medical Corporation stock logo
DERM
Journey Medical
$56.13M2.98N/AN/A$0.91 per share7.90
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.67M1.00N/AN/A($0.06) per share-32.50
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$36.56M19.74N/AN/A$4.32 per share3.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$220.66M-$0.88N/AN/AN/AN/A-52.82%-29.67%8/14/2025 (Estimated)
Journey Medical Corporation stock logo
DERM
Journey Medical
-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$88.98M$0.7916.73N/AN/A26.33%19.08%15.72%8/6/2025 (Estimated)

Latest DERM, FBIO, AUTL, and STOK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.2329N/AN/AN/A$12.92 millionN/A
8/12/2025Q2 2025
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.31N/AN/AN/A$14.53 millionN/A
8/11/2025Q2 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.06N/AN/AN/A$14.93 millionN/A
8/6/2025Q2 2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$0.0905N/AN/AN/A$31.51 millionN/A
5/14/2025Q1 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million
5/8/2025Q1 2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/AN/AN/AN/AN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/A
9.24
9.02
Journey Medical Corporation stock logo
DERM
Journey Medical
1.07
1.34
1.03
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.74
1.72
1.55
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
8.41
8.41

Institutional Ownership

CompanyInstitutional Ownership
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
72.83%
Journey Medical Corporation stock logo
DERM
Journey Medical
7.25%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
25.70%
Journey Medical Corporation stock logo
DERM
Journey Medical
15.03%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
27.90%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
9.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
330266.14 million197.74 millionOptionable
Journey Medical Corporation stock logo
DERM
Journey Medical
9023.30 million19.80 millionN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million21.32 millionOptionable
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
10054.60 million49.41 millionOptionable

Recent News About These Companies

Case builds for Biogen, Stoke's Dravet syndrome drug
Aston Villa want Stoke City midfielder Sol Sidibe
Live updates after 'accident' on Stoke-on-Trent road

New MarketBeat Followers Over Time

Media Sentiment Over Time

Autolus Therapeutics stock logo

Autolus Therapeutics NASDAQ:AUTL

$2.41 -0.01 (-0.41%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.40 -0.01 (-0.21%)
As of 07/18/2025 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$7.19 -0.11 (-1.51%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$7.20 +0.00 (+0.07%)
As of 07/18/2025 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.95 +0.02 (+1.04%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.97 +0.02 (+0.82%)
As of 07/18/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Stoke Therapeutics stock logo

Stoke Therapeutics NASDAQ:STOK

$13.22 +0.87 (+7.04%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$13.54 +0.32 (+2.46%)
As of 07/18/2025 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.